Quantcast
Last updated on April 16, 2014 at 7:00 EDT

Latest Thiophenes Stories

2014-03-31 08:29:45

RARITAN, N.J., March 31, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today it is adding three new clinical trials to its EXPLORER global cardiovascular research program for XARELTO(®) (rivaroxaban), the most studied and broadly indicated oral Factor Xa inhibitor in the world today. The additional trials will evaluate rivaroxaban for the treatment or prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) in pediatric and other patient...

2014-03-28 12:22:00

DUBLIN, Mar. 28, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/8gxjqj/investigation ) has announced the addition of the "Investigation Report on China's Tiotropium Bromide Market, 2009-2018" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) As the air becomes more contaminated, incidence of asthma and chronic obstructive pulmonary diseases also increases. Consequently, more market space is provided for relevant drug...

2014-03-25 00:23:16

DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/rt6msb/investigation) has announced the addition of the "Investigation Report on China Duloxetine Market" [http://www.researchandmarkets.com/research/rt6msb/investigation ] report to their offering. <start_newscom> (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Depression is a common mood disorder that belongs to high-incidence mental...

2014-01-16 16:24:28

RARITAN, N.J., Jan. 16, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee has voted against the approval of the use of XARELTO(®) (rivaroxaban), an oral anticoagulant, to reduce the risk of thrombotic cardiovascular events in patients with Acute Coronary Syndrome (ACS) in combination with standard antiplatelet therapy. Janssen is seeking approval of...

2013-12-12 12:27:32

MUMBAI, India and BALTIMORE, December 12, 2013 /PRNewswire/ -- Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has launched its Duloxetine Hydrochloride Delayed-release (HCl DR) Capsules 20 mg, 30 mg and 60 mg strengths. The Company received final approval to market its Duloxetine HCl DR Capsules USP, 20 mg, 30 mg, 40 mg and 60 mg strengths from the United States Food and Drugs Administration (FDA) yesterday....

2013-12-03 16:25:03

XARELTO® is the Most Prescribed Novel Oral Anticoagulant in the U.S. Market Today RARITAN, N.J., Dec. 3, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today that new data involving its novel oral anticoagulant XARELTO(®) (rivaroxaban) will be presented at the 55(th) American Society of Hematology (ASH) Annual Meeting and Exposition held in New Orleans, LA, USA, from December 7-10, 2013. Notable presentations at ASH's Annual Meeting and Exposition include:...

2013-10-08 23:24:44

Reportbuyer.com just published a new market research report: Chronic Obstructive Pulmonary Disease (COPD) Market to 2019 - Highly-Priced New Combination Products Forecast to Capture Significant Market Share and Drive Growth. London (PRWEB) October 08, 2013 Summary GBI Research, a leading business intelligence provider, has released its latest research report “Chronic Obstructive Pulmonary Disease (COPD) Market to 2019 - Highly-Priced New Combination Products Forecast to Capture...

2013-09-20 08:25:45

Analysis Published in the Thrombosis Journal RARITAN, N.J., Sept. 20, 2013 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. (Janssen) announced today a newly published, pooled analysis of the Phase III EINSTEIN trial program, showing XARELTO(®) (rivaroxaban) is as effective as the standard of care in reducing the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) in people with symptomatic DVT or PE, while reducing the incidence of major bleeding by 46 percent. The analysis also...

2013-09-09 08:28:07

DORVAL, QC, Sept. 9, 2013 /CNW/ - Novartis announced new analyses of data for investigational QVA149 (indacaterol 85 mcg/glycopyrronium 43 mcg delivered dose, equivalent to 110 mcg/50 mcg metered dose per capsule), which showed clinically significant improvements in lung function, shortness of breath and health-related quality of life for chronic obstructive pulmonary disease (COPD) patients versus those comparators evaluated in the study(1,2).( )These data were part of 39...

2013-09-08 20:20:21

Results presented for the first time at the European Respiratory Society (ERS) Annual Congress 2013 RIDGEFIELD, Conn., Sept. 8, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced the results of TIOSPIR(TM) (Tiotropium Safety and Performance in Respimat) (NCT01126437), one of the largest international chronic obstructive pulmonary disease (COPD) trials conducted to date, at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona, Spain. The...